Your session is about to expire
← Back to Search
CST-2032 and CST-107 for Dementia
Study Summary
This trial will test a new drug to see if it improves cognition in people with mild cognitive impairment or mild dementia.
- Dementia
- Mild Cognitive Impairment
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have early signs of memory loss or mild dementia caused by Parkinson's disease or Alzheimer's disease, but do not experience hallucinations.You are a woman who is currently nursing a baby.The researcher believes it's not in your best interest to join the study for some other reason.You have high blood pressure that is not under control even with medication and lifestyle changes.Your reduced cognitive abilities are not due to a head injury or other medical issues.You have symptoms of certain brain disorders like trouble with movement or balance, dementia, history of stroke, head injury or encephalitis, or other neurological conditions.You have a history of seizures, brain injury, or serious mental health conditions like schizophrenia or bipolar disorder. You may still be eligible if you have depression that is under control.You need to score between 18 and 26 in a cognitive assessment called the Montreal Cognitive Assessment (MoCA).You have had thoughts of committing suicide and have made a plan to do so within the past 3 months.
- Group 1: CST-2032 (3mg)/CST-107 (3mg) to Placebo
- Group 2: CST-2032 (6mg)/CST-107 (3mg) to Placebo
- Group 3: Placebo to CST-2032 (3mg)/CST-107 (3mg)
- Group 4: Placebo to CST-2032 (6mg)/CST-107 (3mg)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently accepted into this clinical research trial?
"Correct. According to the information posted on clinicaltrials.gov, this medical trial is accepting applicants from April 12th 2022 and needs 40 participants across 12 sites. The details of the trial were last refreshed on October 4th 2022."
What goals is this experiment hoping to accomplish?
"The primary parameters of assessment in this clinical trial are Change from Baseline after 14 days of treatment as recorded by Electrocardiograms (ECGs). Secondary measures include changes to cognitive abilities, such as sustained attention and memory recall capabilities, which will be assessed through CANTAB Rapid Visual Information Processing, Verbal Recognition Memory, and Adaptive Tracking Task."
Does this trial admit participants over the age of twenty?
"This clinical trial seeks patients aged 50 to 80. There are 55 studies for minors and 1110 for seniors."
Are there any Canadian medical facilities conducting the research on this project?
"Currently, 12 different sites are enrolling participants into this research trial. These locations include Round Rock, Miami and Winter Park plus an additional 9 more cities. It is advised to select the closest option for you in order to minimise any travelling needs upon registering."
Are there any criteria for eligibility to participate in this trial?
"This clinical investigation requires 40 participants with dementia, aged between 50-80 years old. A detailed list of criteria is presented below: Male or female subjects ≥50 and ≤ 80 years of age at the time they provide informed consent; diagnosis of mild cognitive impairment OR mild dementia due to either Parkinson's disease associated with REM sleep behavior disorder (RBD+PD) and positive response to the RBD Single-Question Screen (RBD1Q) without hallucinations OR Alzheimer's disease (AD); if subject is taking a single drug for AD must have been on stable dose for two months prior to Day 1 and remain unchanged unless required due to adverse"
Is this clinical research currently recruiting participants?
"According to records maintained on clinicaltrials.gov, this research is still recruiting participants and was initially posted online in April of 2022 with the most recent update taking place in October that same year."
Are there any significant safety risks associated with the use of CST-2032 (3mg)/CST-107 (3mg) compared to a Placebo?
"Our team at Power gave CST-2032 (3mg)/CST-107 (3mg) to Placebo a score of 2, as the Phase 2 trial has only presented limited data on its safety but yet to provide evidence for efficacy."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Most responsive sites:
- CuraSen Investigational Site - Bradenton: < 48 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger